Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Asset Writedowns and Impairment: 2022-2024

Historic Asset Writedowns and Impairment for InMed Pharmaceuticals (INM) over the last 1 years, with Jun 2024 value amounting to $42,408.

  • InMed Pharmaceuticals' Asset Writedowns and Impairment rose 115.83% to $42,408 in Q2 2024 from the same period last year, while for Jun 2024 it was $37,977, marking a year-over-year change of. This contributed to the annual value of $2,424 for FY2025, which is 99.21% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Asset Writedowns and Impairment of $42,408 as of Q2 2024, which was down 75.12% from $170,474 recorded in Q4 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Asset Writedowns and Impairment peaked at $576,772 during Q3 2022, and registered a low of -$267,835 during Q2 2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Asset Writedowns and Impairment value was $92,930 (recorded in 2023), while the average stood at $122,950.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Asset Writedowns and Impairment tumbled by 83.89% in 2023, and later surged by 115.83% in 2024.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment (Quarterly) stood at $576,772 in 2022, then plummeted by 83.89% to $170,474 in 2023, then surged by 115.83% to $42,408 in 2024.
  • Its last three reported values are $42,408 in Q2 2024, $170,474 for Q4 2023, and $92,930 during Q3 2023.